Washington, D.C. – Representative John Curtis issued the following statement after the announcement by Eli Lilly and Company to lower the cost of certain insulin products in the United States by forty percent effective January 2022:

“I regularly hear from Utahns about the high cost of insulin and I applaud the leadership at Eli Lilly in taking the unprecedented step to drastically lower this expense without government intervention,” said Rep. Curtis. “Reducing prescription drug prices remains a top policy priority for me in Congress and I will continue to work with industry, patients, and providers to identify long-term solutions that increase access to medication and drive American innovation in bringing more life-saving cures to the marketplace.”